Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis drug shows promise in Mid-Stage trial

NCT ID NCT06592274

Disease control Sponsor: Huabo Biopharm Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 2 trial is testing a new biologic drug called HB0017 in 200 adults with moderate to severe plaque psoriasis. Participants receive different doses and schedules of the injection to see how well it clears skin plaques and how safe it is. The study is double-blind and randomized, meaning neither patients nor doctors know who gets which dose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HB0017 injection (a biologic drug)
What this could lead to
If successful, this could lead to a new treatment option that helps clear psoriasis plaques with less frequent injections.
What could go wrong
This is an early Phase 2 trial with only 200 people, so results may not apply to everyone. The drug may not work better than existing treatments or could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects aged 18-75 years (inclusive) * Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization. * Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score \>=3. * Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator * Subjects who are able to use effective contraception from the screening period to 6 months after the last dose Exclusion Criteria: * Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis * Ongoing use of prohibited treatments * Any active infection (other than common cold) within 14 days * Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization * Have previously received any drug that directly targets IL-17 or IL-17 receptor * Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization * A history of inflammatory bowel disease or other serious autoimmune disease * Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis (PSO) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis (PSO)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chongqing Traditional Chinese Medicine Hospital

    RECRUITING

    Chongqing, Sichuan, China

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, China

  • Hangzhou First People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

  • Jiangsu University Affiliated Hospital

    RECRUITING

    Zhenjiang, Jiangsu, China

  • Jiaxing First Hospital

    RECRUITING

    Jiaxing, Zhejiang, China

  • Jilin University Second Hospital

    RECRUITING

    Changchun, Jilin, China

  • Jining First People's Hospital

    RECRUITING

    Jining, Shandong, 0531, China

  • Ningbo Second Hospital

    RECRUITING

    Ningbo, China

  • Shandong First Medical University Affiliated Dermatology Hospital

    NOT_YET_RECRUITING

    Jinan, Shandong, 0531, China

  • Shanxi Medical University Second Hospital

    RECRUITING

    Taiyuan, Shanxi, China

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, China

  • Southern Medical University Dermatology Hospital

    RECRUITING

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Bengbu Medical College

    RECRUITING

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

  • Wenzhou Medical University Affiliated First Hospital

    RECRUITING

    Wenzhou, Zhejiang, China

  • Wuxi Second People's Hospital

    RECRUITING

    Wuxi, Jiangsu, China

  • Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, China

  • Xingtai People's Hospital

    RECRUITING

    Xingtai, Shandong, 0531, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.